Glucose evaluation trial for remission (GETREM) in type 1 diabetes: a European multicentre study P. Pozzilli a, * , S. Manfrini a , R. Buzzetti a , E. Lampeter b , I.De. Leeuw c , D. Iafusco d , M. Prisco d , C. Ionescu-Tirgoviste e , S. Kolouskova ` f , T. Linn g , J. Ludvigsson h , L. Mada `csy i , A.Seremak. Mrozikiewicz j , P.M. Mrozikiewicz j , T. Podar k , J. Vavrinec f , B. Vialettes l , N. Visalli a , T. Yilmaz m , P.D. Browne n IMDIAB group Rome, Italy a Department of Endocrinology and Diabetes, University Campus Bio-Medico, Via E. Longoni, 83, 00155 Rome, Italy b Du ¨sseldorf, Germany c Antwep, Belgium d Naples, Italy e Bucharest, Romania f Pragu, Czech Republic g Giessen, Germany h Linkoping, Sweden i Budapest, Hungary j Poznan, Poland k Tartu, Estonia l Marseille, France m Istanbul, Turkey n London, UK Received 21 April 2004; received in revised form 5 October 2004; accepted 6 October 2004 Available online 21 November 2004 Abstract Objective: Strict metabolic control during the 1st year of type 1 diabetes is thought to be a key factor for achieving clinical remission. The aims of this study were two-fold: (i) to evaluate the frequency and duration of spontaneous remission (defined according to the parameters issued by the International Diabetic Immunotherapy Group (IDIG)) in a European population of consecutive recent onset type 1 diabetes patients (aged 5–35 years), followed-up for a period of 36 months with a common www.elsevier.com/locate/diabres Diabetes Research and Clinical Practice 68 (2005) 258–264 * Corresponding author. Tel.: +39 06 22541 556; fax: +39 06 22541 336. E-mail address: pozzilli@unicampus.it (P. Pozzilli). 0168-8227/$ – see front matter # 2004 Elsevier Ireland Ltd. All rights reserved. doi:10.1016/j.diabres.2004.10.001